Clinical Trial to Evaluate the Regeneration of Articular Cartilage Through Arthroscopy After MegaCarti® Application - Trial NCT06278480
Access comprehensive clinical trial information for NCT06278480 through Pure Global AI's free database. This phase not specified trial is sponsored by L&C Bio and is currently Recruitment Completed. The study focuses on Osteoarthritis, Knee. Target enrollment is 40 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
L&C Bio
Timeline & Enrollment
N/A
Jun 23, 2023
Feb 29, 2024
Primary Outcome
Comparison of the ICRS-Cartilage Repair Assessment grade-Overall repair assessment,Comparison of macroscopic status of regenerated cartilage
Summary
The MegaCarti® is the decellularized allogeneic cartilage and acts as a cover after bone
 marrow stimulation to prevent the loss of blood clots and induces cartilage regeneration by
 assisting in the location of stem cells derived from bone marrow. During the 48-week
 confirmatory clinical trial of MegaCarti®, patients who simultaneously underwent high tibial
 osteotomy(HTO) were treated with a group in which MegaCarti® was implanted after
 microfracture and a group in which microfracture alone was performed. Cartilage regeneration
 is evaluated in patients with arthroscopy data at the time of fixation removal surgery.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06278480
Device Trial